Recent discussions around Polycystic Ovary Syndrome (PCOS) have highlighted the potential for a name change, driven by emerging evidence of a male version of the condition.
This shift in nomenclature reflects a broader understanding of hormonal disorders and their impact across genders, suggesting that the current terminology may not adequately encompass the experiences of all affected individuals.
As the evidence base grows, stakeholders in the healthcare and research communities may need to consider the implications of this change for diagnosis, treatment, and public awareness.